Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk Q4: Slumping Due To Weak Guidance
Novo Nordisk A/S shares dropped ~20% after issuing weaker-than-expected 2026 guidance despite strong 2025 obesity drug growth. NVO's 2025 revenue rose 10% at constant currency rates, but margin compression and higher costs left net profit flat; the obesity franchise grew 31%. 2026 guidance forecasts ~9% constant currency revenue and profit decline, driven by U.S. drug pricing pressures and patent expirations.
Novo to launch Ozempic pill for diabetes in second quarter of this year
Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year.
Novo Nordisk: My Certainties Swept Away By A Quarterly Report (Downgrade)
Novo Nordisk A/S faces disappointing 2026 guidance, projecting a 5–13% revenue and operating profit decline despite Wegovy pill adoption. Margin pressure arises as the oral Wegovy pill is costlier to produce and priced lower than injectables, compressing profitability even amid surging demand. US pricing pressure, currency headwinds, and competition from Eli Lilly compound risks, pushing NVO's FWD price/FCF multiple to 33x amid deteriorating fundamentals.
Novo Nordisk Stock Sinks on Weak Sales Forecast
Novo Nordisk A/S (NYSE:NVO) stock is extending last session's 14.6% slide, down 3.7% to trade at $48.44 at last glance.
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
Novo Nordisk plunge wipes $50 billion off obesity drug giant
Novo Nordisk shares tumbled 16% on Wednesday, wiping off around $50 billion from the Wegovy maker's market capitalization after it warned on Tuesday its sales and profits would fall in 2026.
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
Having pre-announced earnings a day earlier, Novo Nordisk CEO Mike Doustdar, faced the European media Wednesday morning and gave a series of downbeat assessments of the company's prospects in 2026.
Wegovy Maker Novo Nordisk's Shares Slump After Guidance Disappoints
The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
"People should expect that it goes down before it comes back up," CEO Mike Doustdar told CNBC's "Early Edition Europe" on Wednesday. In this article NVO
Novo Nordisk's shock 2026 guidance points to obesity battle heating up
Danish obesity drug giant Novo Nordisk is set to be punished by investors on Wednesday after it gave a far bleaker-than-expected outlook for 2026 and flagged a tough weight-loss market battle ahead as prices come under pressure.
Novo Nordisk: Compressing Margins And Collapsing Guidance Confirm Sell Thesis
Novo Nordisk A/S faces a structural margin crisis as oral Wegovy cannibalizes its high-margin injectable business. NVO Q4 2025 results confirm margin contraction: net margin fell 170 bps to 33.1%, with operating profit down 1% despite 6% sales growth. 2026 guidance forecasts adjusted NVO sales and EBIT to decline by -5% to -13%, driven by lower realized prices and higher input costs.
